Infectious Diseases 2019

Infectious Diseases 2019

Antibiotic resistance threats in the USA

19 December, 2019

CDC’s Antibiotic Resistance Threats in the United States, 2019 (2019 AR Threats Report) includes the latest national death and infection estimates that underscore the continued threat of antibiotic resistance in the U.S. According to the report, more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. Dedicated prevention and infection control efforts in the U.S. are working to reduce the number of infections and deaths caused by antibiotic-resistant germs, but the number of people facing antibiotic resistance is still too high. More action is needed to fully protect people. CDC is concerned about rising resistant infections in the community, which can put more people at risk, make spread more difficult to identify and contain, and threaten the progress made to protect patients in healthcare. The emergence and spread of new forms of resistance remains a concern.
The report lists 18 antibiotic-resistant bacteria and fungi into three categories based on level of concern to human health - urgent, serious, and concerning. The report also includes a Watch List with three threats that have not spread resistance widely in the U.S. but could become common without a continued aggressive approach.
Campylobacter
Campylobacter infections with decreased susceptibility are more common in low- and middle-income countries, putting travelers at risk for infections that may be harder to treat. The percentage of Campylobacter with decreased susceptibility to ciprofloxacin has almost doubled in 20 years, limiting treatment options for patients.
Salmonella
Antibiotics such as ciprofloxacin, azithromycin, and ceftriaxone are sometimes needed to treat patients with severe Salmonella infections. Resistant Salmonella infections can be more severe and have higher hospitalization rates. Antibiotic-resistant nontyphoidal Salmonella infections are on the rise and approaching 10% for ciprofloxacin in 2017.

Related Links
Link The report